

┆

This document, which comprises a supplementary prospectus relating to the Company prepared in accordance with the Prospectus Rules, has been filed with the FSA in accordance with Rule 3.2 of the Prospectus Rules and approved as a supplementary prospectus by the FSA under section 87A of FSMA.

LR 2.2.10(2)

This document is supplemental to and must be read in conjunction with the price range prospectus published by the Company on 22 February 2006 (the "Prospectus"). Save as disclosed in this supplementary prospectus, since the publication of the Prospectus there have been no significant new factors, material mistakes or inaccuracies relating to the information contained in the Prospectus other than those disclosed in this document. In particular, when considering whether to purchase Shares, you should take account of the factors described in Part II (Risk Factors) of the Prospectus. Except where the content otherwise requires, terms defined in the Prospectus have the same meaning when used in this document.

The Company and the Directors of the Company, whose names appear in paragraph 2 of Part II (Additional Information) of this document, accept responsibility for the information contained herein. To the best of the knowledge and belief of the Company and the Directors (who have taken all reasonable care to ensure that such is the case), the information contained in this document is in accordance with the facts and does not omit anything likely to affect the import of such information.

This document does not constitute or form part of any offer or invitation to sell or issue, or any solicitation of any offer to purchase or subscribe for any securities other than the Shares to which it relates, or any offer or invitation to sell or issue, or any solicitation of any offer to purchase or subscribe for such Shares by any person in any circumstances or jurisdiction in which such offer or solicitation is unlawful.

This document is not for publication or distribution in Australia, Canada, Japan or the United States. The Shares have not been and will not be registered under the Securities Act or with any securities regulatory authority of any state or jurisdiction in the United States or under the applicable securities laws of Australia, Canada or Japan and may not be offered, sold or otherwise transferred, directly or indirectly, in or into Australia, Canada, Japan or the United States or for the account or benefit of citizens or residents of Australia, Canada or Japan, subject to certain exceptions determined by the Company in its sole discretion and pursuant to the applicable laws. The restrictions that apply to the distribution of the Prospectus also apply to the distribution of this document. Potential investors with registered addresses in overseas territories are required by the Company and UBS to inform themselves about and observe any restrictions on the offer, sale or transfer of the Shares and the distribution of the Prospectus and to refer to paragraph 10 of Part X (Details of the Offer) of the Prospectus for further information.

Rightmove plc

*(incorporated in England and Wales under the
Companies Act 1985 with registered number 3997679)*

Ann I, 5.1.1

Supplementary Prospectus

Ann III, 5.1.2

Offer of 22,668,866 Shares of 1p each at an Offer Price expected to be between 275p and 335p per Share and admission to the Official List and trading on the London Stock Exchange

UBS Investment Bank

Sponsor, Global Co-ordinator, Financial Adviser and Sole Bookrunner

Panmure Gordon & Co.

Co-Lead Manager

Expected share capital immediately following Admission

Number	Authorised			Issued and fully paid	
	Amount	Amount		Number	Amount
300,000,000	£3,000,000		ordinary shares of 1p each	126,761,800	£1,267,618

The Revised Price Range is indicative only, it may change during the course of the Offer and the Offer Price may be set within, above or below the Revised Price Range. If the Revised Price Range does change during the course of the Offer the Company would not envisage making an announcement until determination of the Offer Price, unless required to do so by law. The Company expects to announce the Offer Price and publish a pricing statement on or about 10 March 2006. Further details of how the Offer Price is to be determined are contained in Part X (Details of the Offer) of the Prospectus.

Application has been made to the UK Listing Authority for the whole of the issued and to be issued share capital of the Company to be admitted to the Official List and to London Stock Exchange plc for the issued share capital of the Company to be admitted to trading on the London Stock Exchange's market for listed securities. Conditional dealings in the Shares are expected to commence on the London Stock Exchange at 8.00 a.m. (London time) on 10 March 2006. It is expected that Admission will become effective and that unconditional dealings in Shares will commence at 8.00 a.m. (London time) on 15 March 2006. Application has not been and is not intended to be made for such Shares to be admitted to, or to trade on, any other stock exchange. Any dealings before the commencement of unconditional dealings will be of no effect if Admission does not take place and such dealings will be at the sole risk of the parties concerned.

LR 2.2.9(1)
LR 2.2.3

Ann III, 6.1

UBS Limited ("UBS" or "UBS Investment Bank") is acting exclusively for the Company and the Corporate Selling Shareholders and no-one else in connection with the Offer and will not be responsible to anyone other than the Company and the Corporate Selling Shareholders for providing the protections afforded to clients of UBS, nor for providing advice in relation to the Offer, the contents of this document or any transaction, arrangement or other matter referred to herein.

Panmure Gordon (UK) Limited ("Panmure Gordon") is acting exclusively for the Company and no-one else in connection with the Offer and will not be responsible to anyone other than the Company for providing the protections afforded to the clients of Panmure Gordon, nor for providing advice in relation to the Offer, the contents of this document or any transaction, arrangement or other matter referred to herein.

UBS and Panmure Gordon make no representation, express or implied, with respect to the accuracy or completeness of any information contained in this document, and accept no responsibility for, nor do they authorise, the contents of this document, including without limitation under Rule 5.5 of the Prospectus Rules.

Prospective investors should only rely on the information contained in this document and in the Prospectus. No person has been authorised to give any information or make any representation other than those contained in this document and the Prospectus; if given or made, such information must not be relied upon as having been authorised by the Company, the Directors, the Selling Shareholders, UBS or Panmure Gordon. In particular, the content of the Rightmove Website does not form part of this document and prospective investors should not rely on it.

Without prejudice to any legal or regulatory obligation on the Company to publish a further supplementary prospectus pursuant to section 87G of FSMA and Rule 3.4 of the Prospectus Rules, neither the delivery of this document nor any sale made pursuant to it shall, under any circumstances, create any implication that there has been no change in the affairs of the Company or the Group taken as a whole since the date of this document or that the information contained herein is correct as of any time subsequent to the date of this document.

The contents of this document are not to be construed as legal, business or tax advice. Each prospective investor should consult their own legal adviser, financial adviser or tax adviser for legal, financial or tax advice.

┆

┆

RESTRICTIONS ON SALES OUTSIDE THE UNITED KINGDOM

THE SHARES HAVE NOT BEEN APPROVED OR DISAPPROVED BY THE UNITED STATES SECURITIES AND EXCHANGE COMMISSION, ANY STATE SECURITIES COMMISSION IN THE UNITED STATES OR ANY OTHER REGULATORY AUTHORITY IN THE UNITED STATES, NOR HAVE ANY OF THE FOREGOING AUTHORITIES PASSED ON OR ENDORSED THE MERITS OF THE OFFER OR THE ACCURACY OR ADEQUACY OF THE INFORMATION CONTAINED IN THIS DOCUMENT. ANY REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENCE IN THE UNITED STATES.

The distribution of this document and the offer and issue of the Shares in certain jurisdictions may be restricted by law and therefore persons into whose possession this document should come should inform themselves about and observe any such restrictions. Any failure to comply with these restrictions may constitute a violation of the securities laws of such jurisdiction. No action has been or will be taken by the Company, UBS, Panmure Gordon, the Selling Shareholders or any other person that would permit an offer of Shares or possession or distribution of this document or any other offering or publicity material or application form relating to the Shares in any jurisdiction where action for that purposes is required, other than in the United Kingdom. This document does not constitute an offer of or the solicitation of an offer to buy or subscribe for Shares in any jurisdiction in which such offer or invitation would be unlawful. The restrictions that apply to the distribution of the Prospectus also apply to the distribution of this document. Further information with regard to restrictions on offers and sales of the Shares and the distribution of the Prospectus are set out in Part X (Details of the Offer) of the Prospectus.

FORWARD-LOOKING STATEMENTS

This document contains certain “forward-looking statements”, including statements about current beliefs and expectations of the Directors. In particular, the words “expect”, “anticipate”, “estimate”, “may”, “should”, “plans”, “intends”, “will”, “believe” and similar expressions (or in each case their negative and other variations or comparable terminology) can be used to identify forward-looking statements. These statements are based on the Board’s expectations of external conditions and events, current business strategy, plans and the other objectives of management for future operations, and estimates and projections of the Company’s financial performance. Though the Board believes these expectations to be reasonable at the date of this document they may prove to be erroneous. Forward-looking statements involve known and unknown risks and uncertainties and speak only as of the date they are made. Investors are hereby cautioned that certain important factors could cause actual results, outcomes, performance or achievements of the Company, or industry results to differ materially from those expressed or implied in forward-looking statements. These factors include, but are not limited to those described in Part II (Risk Factors) of the Prospectus.

Save as required by law, the Listing Rules or the Disclosure Rules, the Company undertakes no obligation to publicly release the results of any revisions to any forward-looking statements in this document that may occur due to any change in the Board’s expectations or to reflect events or circumstances after the date of this document.

UNDERWRITERS DEALINGS

In connection with the Offer, UBS and any of its affiliates acting as an investor for its own account may subscribe for or purchase Shares and, in that capacity, may retain, purchase, sell, offer to sell or otherwise deal for its or their own account(s) in such securities, any other securities of the Company or other related investments in connection with the Offer or otherwise. Accordingly, references in this document to the Shares being issued, offered, subscribed or otherwise dealt with should be read as including any issue or offer to, or subscription, purchase or dealings by, UBS and any of its affiliates acting as an investor for its own accounts. UBS does not intend to disclose the extent of any such investment or transaction otherwise than in accordance with any legal or regulatory obligation to do so.

┆

⊥

Part I – Significant New Information

THIS DOCUMENT IS SUPPLEMENTAL TO, AND SHOULD BE READ IN CONJUNCTION WITH, THE PROSPECTUS.

1. Introduction

- 1.1 Based on indications of interest in acquiring Shares under the Institutional Offer which have been received at the date of this document, the Offer Price may be set above the upper end of the Price Range. The Directors have decided to revise the Price Range upwards.
- 1.2 Any statement contained in the Prospectus shall be deemed to be modified or superseded to the extent that a statement in this document modifies or supersedes such statement.

2. Revised Price Range

- 2.1 The Price Range, as described in Part X (Details of the Offer) of the Prospectus, was originally set at 240p to 315p per Share. For the reasons described in paragraph 2.2 of this Part I, the Revised Price Range will be 275p to 335p per Share.
- 2.2 As at the date of this document, indications of interest in acquiring Shares under the Institutional Offer have been received by UBS such that the bookbuilding process may result in the Offer Price being set above the upper end of the Price Range.
- 2.3 It is currently expected that the Offer Price (which will be the same for all Shares sold pursuant to the Institutional Offer, the Customer Offer and the Employee Offer) will be within the Revised Price Range, but this range remains indicative only and may change during the course of the Offer. The Offer Price may be set within, above or below the Revised Price Range.
- 2.4 References to the Price Range in the Prospectus are now deemed to be references to the Revised Price Range. In addition, there are several places in the Prospectus where the mid-point of the Price Range is referred to or otherwise forms the basis for a calculation or estimate. These references shall now be deemed to be the mid-point of the Revised Price Range with the following effects:
 - (A) In paragraph 1 of Part X (Details of the Offer) of the Prospectus, it is now expected that the Offer will raise approximately £69.1 million for the Selling Shareholders (before commission and other fees and expenses).
 - (B) In paragraph 2 of Part X (Details of the Offer) of the Prospectus, allocations under the Customer Offer and the Employee Offer will not exceed 3,360,656 Shares.
 - (C) In paragraph 5.4 of Part X (Details of the Offer) of the Prospectus, on the basis of an Offer Price of 305p per Share (being the mid-point of the Revised Offer Price), it is now expected that each Eligible Employee who accepts their Employee Free Shares entitlement will receive 163 Shares.
 - (D) In paragraph 5.5 of Part XIII (Additional Information) of the Prospectus, the reference to the mid-point of the Price Range is deemed to be a reference to the mid-point of the Revised Price Range being 305p per Share.
 - (E) In paragraph 5.7 of Part XIII (Additional Information) of the Prospectus, on the basis of an Offer Price set at the mid-point of the Revised Price Range the Company will issue 44,262 Shares to Mr Agnew as soon as practicable after Admission.
 - (F) In paragraph 5.8 of Part XIII (Additional Information) of the Prospectus, on the basis of an Offer Price set at the mid-point of the Revised Price Range the Company will issue 39,344 Shares to Mr Cooper as soon as practicable after Admission.

⊥

⊥

Part I – Significant New Information

- (G) In paragraph 5.9 of Part XIII (Additional Information) of the Prospectus, on the basis of an Offer Price set at the mid-point of the Revised Price Range the Company will issue an aggregate of 34,426 Shares to Ms Vezmar.
- (H) In paragraph 7.3 of Part XIII (Additional Information) of the Prospectus, on the basis of an Offer Price set at the mid-point of the Revised Price Range the number of Shares held by The Rightmove Employee Share Trust will be 8,601,178 (comprising 6.8 per cent. of Rightmove’s issued share capital) based on an allocation of 31,622 Employee Free Shares being transferred to Eligible Employees.
- (I) In paragraph 10 of Part XIII (Additional Information) of the Prospectus, on the basis of an Offer Price set at the mid-point of the Revised Price Range, The Rightmove Employee Share Trust would transfer approximately 31,622 Shares to Eligible Employees.
- (J) In the “Offer Statistics” section on page 170 of the Prospectus, on the basis of an Offer Price set at the mid-point of the Revised Price Range the revised statistics will be as follows:

Revised Price Range	275p to 335p
Market capitalisation at the mid-point of the Revised Price Range	£387 million
Proceeds receivable by the Selling Shareholders after expenses	£66.4 million

⊥

⊥

Part II – Additional Information

1. Persons responsible

The Company and the Directors, whose names appear in paragraph 2 of this Part II below, accept responsibility for the information contained in this document. To the best of the knowledge and belief of the Company and the Directors (who have taken all reasonable care to ensure that such is the case), the information contained in this document is in accordance with the facts and does not omit anything likely to affect the import of such information.

2. Directors

The Directors of Rightmove are:

Scott Edward Forbes	Executive Chairman
Edmund Warren Williams	Group Managing Director
James Graham Zacharias	Group Finance Director
Nicholas James McKittrick	Managing Director of Rightmove.co.uk
Harry Douglas Hill	Non-executive Director
Reginald Stephen Shipperley	Non-executive Director
Jane Pridgeon	Non-executive Director
Jonathan Geoffrey William Agnew	Senior independent non-executive Director
Nigel William Cooper	Non-executive Director
Judith Vezmar	Non-executive Director

Biographical details for each of the Directors are set out in paragraph 2 of Part IV (Directors, Senior Managers, Corporate Governance and Principal Shareholders) of the Prospectus.

3. Documents available for inspection

In addition to those documents set out in paragraph 20 of Part XIII (Additional Information) of the Prospectus, copies of this document will be available for inspection during normal business hours on Monday to Friday each week (public holidays excepted) from the date of publication of this document until Admission at the offices of Slaughter and May, One Bunhill Row, London EC1Y 8YY.

Additional definitions

“Revised Price Range”	275p to 335p, being the revised indicative range of prices set out in this document between which the Offer Price is expected to be set (although the Offer Price may be set within, above or below this range).
-----------------------	--

⊥